Trials / Recruiting
RecruitingNCT05684692
Screening Trial for Pain Relief in Schwannomatosis (STARFISH)
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Massachusetts General Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a placebo-controlled, multi-arm phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN). This Master Study is being conducted as a platform that may allow participants with pain associated with schwannomatosis to receive a novel intervention throughout this study. Embedded within the Master Study are individual drug sub-studies: * Investigational Drug Sub-Study A: Siltuximab * Investigation Drug Sub-Study B: Erenumab-Aooe
Detailed description
This is a placebo-controlled, multi-arm phase II platform screening trial designed to test the safety, pain responses, and pharmacodynamic activity of multiple experimental therapies simultaneously in participants with moderate-to-severe pain due to schwannomatosis (SWN). The MASTER STUDY has no study drug or intervention. It is intended to enroll participants who will be placed into different treatment arms (SUB-STUDIES), which will each have an additional consent and enrollment process. MASTER STUDY * The research study procedures include screening for eligibility, randomization to an experimental treatment sub-study, if qualified, and observation for up to 10 years. * Subjects who complete treatment on one experimental arm will be permitted to enroll in a different experimental treatment arm if they meet eligibility criteria. * Participants who are not eligible for enrollment in a different treatment sub-study will be permitted to remain under observation on this Master Study to understand the natural history of schwannomatosis-related pain and tumor growth pattern. * Participants will be eligible to remain on this Master Study for up to 10 years. * It is expected that about 40 people will take part in the Master Study. * The study will randomize a maximum of 20 participants to each of the experimental arms. The overall size of the trial is not fixed by design because it includes arm-dropping rules for futility and allow for the possibility of arm addition by amendment. * Upon meeting Master Study qualifications, participant will be randomly assigned to a treatment sub-study. SUB-STUDY A - SILTUXIMAB * The purpose of this study is to find out what effects, good and/or bad, siltuximab has on schwannomatosis-associated pain. * The U.S. Food and Drug Administration (FDA) has not approved Siltuximab for schwannomatosis but it has been approved for the treatment of people with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV) negative and human herpesvirus-8 (HHV-8) negative. * Siltuximab was identified as a potential treatment for schwannomatosis tumors in a screen of compounds in a laboratory. Siltuximab is believed to work by blocking the growth signals and inflammation in tumor cells. * Upon meeting sub-study qualifications, participant will be randomly assigned to either the early-start group or the delayed-start group. * Twenty (20) people will take part in the siltuximab Sub-study. * Participants in the early-start group will receive siltuximab every 3 weeks over 168 days. Participants in the delayed-start group will receive placebo every 3 weeks for the first 84 days followed by siltuximab every 3 weeks over the subsequent 84 days (for a total of 168 days). SUB-STUDY B - ERENUMAB-AOOE * The purpose of this study is to find out what effects, good and/or bad, erenumabaooe has on schwannomatosis-associated pain. * The U.S. Food and Drug Administration (FDA) has not approved Erenumab-Aooe for schwannomatosis but has approved it for treatment of migraines headaches in adults. * Erenumab-Aooe was identified as a potential treatment for schwannomatosis pain. Erenumab-aooe acts by blocking pain signals in the body. By blocking pain signals, erenumabaooe may reduce pain associated with schwannomatosis. * Upon meeting sub-study qualifications, participant will be randomly assigned to either the early-start group or the delayed-start group. * Twenty (20) people will take part in the ERENUMAB-AOOE Sub-study. * Participants in the early-start group will receive erenumab-aooe every 4 weeks over 168 days. Participants in the delayed-start group will receive placebo every 4 weeks for the first 84 days followed by erenumab-aooe every 4 weeks over the subsequent 84 days (for a total of 168 days).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Siltuximab | A chimeric immunoglobulin G mAb, via intravenous infusion. |
| DRUG | Erenumab-Aooe | Human monoclonal antibody, single-dose prefilled SureClick® autoinjector, via subcutaneous injection. |
| DRUG | Siltuximab Matching Placebo | Dextrose 5% in water, via intravenous infusion. |
| DRUG | Erenumab-Aooe Matching Placebo | 0.9% saline, 1 mL single-dose prefilled syringe, via subcutaneous injection. |
Timeline
- Start date
- 2023-08-31
- Primary completion
- 2026-11-30
- Completion
- 2027-11-30
- First posted
- 2023-01-13
- Last updated
- 2025-10-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05684692. Inclusion in this directory is not an endorsement.